Diabetes Mellitus, Type 2KRIMDNCT04943523
Krill Oil and Muscle Weakness in Type 2 Diabetes
A study testing Krill Oil and Vegetable Oil in people with Diabetes Mellitus, Type 2, run by Dasman Diabetes Institute at 1 site in Kuwait.
Trial summary
The age-related loss of muscle mass and function, sarcopenia, has several deleterious effects, such as a reduction in the quality of life and an increase in the incidence of falls, often leading to hospitalisation. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- Krill Oil and Vegetable Oil
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 150 participants
- Where
- 1 siteKuwait
- Study dates
- 1 May 2022to Aug 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Physician confirmed type 2 diabetes.
- Age >/= 40 years
- No changes in anti-diabetic medication in the last 3 months.
- Muscle weakness (grip strength <27kg and females <16kg)
Who cannot join
- BMI of 45 or higher
- BP of 160/100mmHg or higher
- Cancer or cancer that has been in remission <5 years
- Any medical condition that prevents participants from exercising safely
- On anticoagulant therapy
- Allergies to seafood
- Regular consumption of more than 2 portions of oily fish per week
- Currently consuming omega-3 supplements
Trial locations and contacts
1 site in 1 country.
Kuwait1 site, 1 recruiting
- Recruiting
Dasman Diabetes Institute
Kuwait City, 15462
Ebaa AlOZairi
Ebaa AlOzairi
About this study
Official title: Effects of Krill Oil Supplementation on Muscle Mass and Function in People With Muscle Weakness and Type 2 Diabetes
The age-related loss of muscle mass and function, sarcopenia, has several deleterious effects, such as a reduction in the quality of life and an increase in the incidence of falls, often leading to hospitalisation. The prevalence of sarcopenia is unclear but is estimated to be between 4.6 and 7.9% and the loss of skeletal muscle mass and function is accelerated in people with type 2 diabetes. With the percentage of older people and the percentage of people with type 2 diabetes predicted to rise in coming years it is crucial to develop therapies to increase muscle mass and function. Alterations in nutrition have also been suggested to be of therapeutic use in sarcopenia. Epidemiological data showed that the consumption of fatty fish is positively associated with muscle function in older population, indicating a potential role for long-chain n-3 polyunsaturated fatty acids (LCn-3 PUFA) in increasing muscle mass and function in older people. The aim of the current study, therefore, is to determine the effects of krill oil supplementation on muscle size and function in adults with muscle weakness and type 2 diabetes.
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- Krill Oil, Vegetable Oil
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Krill OilDietary supplement
Krill oil supplements 4g/day
Vegetable OilDietary supplement
vegetable oil supplements 4g/day
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | vegetable oil 4g/day Receives: Dietary Supplement: Vegetable Oil |
| Krill Oil | Active comparator | Krill Oil 4g/day Receives: Dietary Supplement: Krill Oil |
What is being measured
The primary outcome is the main question the study is designed to answer.
Grip strength
Change in Grip strength
Measured: Change from baseline to one year
Secondary outcomes (9)
SPPB
Change in Short performance physical battery test
Measured: Change from baseline to one year
HbA1c
Change in glycated haemoglobin
Measured: Change from baseline to one year
Blood pressure
Change in blood pressure
Measured: Change from baseline to one year
body mass
Change in body mass
Measured: Change from baseline to one year
Lean mass
Change in lean mass
Measured: Change from baseline to one year
Body fat
Change in body fat
Measured: Change from baseline to one year
BMC
Change in bone mineral content
Measured: Change from baseline to one year
BMD
Change in bone mineral density
Measured: Change from baseline to one year
Erythrocyte fatty acid profile
Change in Erythrocyte fatty acid profile
Measured: Change from baseline to one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2021
- Study start1 May 2022
- Primary completionAug 2024 (estimated)
- Study completionAug 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Parallel Group Randomised Controlled Trial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dasman Diabetes Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ebaa AlOzairi, Principal investigator, Dasman Diabetes Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04943523
- Sponsor's protocol ID
- RA HM-2021-010
- Acronym
- KRIMD
- Status last verified
- Jul 2023
- First submitted
- 22 Jun 2021
- Last updated
- 13 Sep 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Krill Oil Supplementation on Muscle Mass and Function in People With Muscle Weakness and Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT04943523
- Acronym / sponsor ID
- KRIMD / RA HM-2021-010
- Conditions
- Diabetes Mellitus, Type 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Dasman Diabetes InstituteUniversity, hospital or other
- Study start
- 1 May 2022 (actual)
- Primary completion
- Aug 2024 (estimated)
- Study completion
- Aug 2024 (estimated)
- First posted
- 29 Jun 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The age-related loss of muscle mass and function, sarcopenia, has several deleterious effects, such as a reduction in the quality of life and an increase in the incidence of falls, often leading to hospitalisation. The prevalence of sarcopenia is unclear but is estimated to be between 4.6 and 7.9% and the loss of skeletal muscle mass and function is accelerated in people with type 2 diabetes. With the percentage of older people and the percentage of people with type 2 diabetes predicted to rise in coming years it is crucial to develop therapies to increase muscle mass and function. Alterations in nutrition have also been suggested to be of therapeutic use in sarcopenia. Epidemiological data showed that the consumption of fatty fish is positively associated with muscle function in older population, indicating a potential role for long-chain n-3 polyunsaturated fatty acids (LCn-3 PUFA) in increasing muscle mass and function in older people. The aim of the current study, therefore, is to determine the effects of krill oil supplementation on muscle size and function in adults with muscle weakness and type 2 diabetes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Parallel Group Randomised Controlled Trial
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Dietary Supplement: Vegetable Oilvegetable oil 4g/day |
| Krill Oil | Active comparator | Dietary Supplement: Krill OilKrill Oil 4g/day |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Physician confirmed type 2 diabetes.
- Age >/= 40 years
- No changes in anti-diabetic medication in the last 3 months.
- Muscle weakness (grip strength <27kg and females <16kg)
Key exclusion criteria (8 listed)
- BMI of 45 or higher
- BP of 160/100mmHg or higher
- Cancer or cancer that has been in remission <5 years
- Any medical condition that prevents participants from exercising safely
- On anticoagulant therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Krill OilKrill oil supplements 4g/day | Dietary supplement | Krill Oil |
| Vegetable Oilvegetable oil supplements 4g/day | Dietary supplement | Placebo |
Primary outcome
Grip strength
Time frame: Change from baseline to one year
Change in Grip strength
9 secondary outcomes
SPPB
Time frame: Change from baseline to one year
HbA1c
Time frame: Change from baseline to one year
Blood pressure
Time frame: Change from baseline to one year
body mass
Time frame: Change from baseline to one year
Lean mass
Time frame: Change from baseline to one year
Body fat
Time frame: Change from baseline to one year
BMC
Time frame: Change from baseline to one year
BMD
Time frame: Change from baseline to one year
Erythrocyte fatty acid profile
Time frame: Change from baseline to one year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Sep 2023.
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ebaa AlOzairi principal investigator
Dasman Diabetes Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Krill Oil and Vegetable Oil in people with Diabetes Mellitus, Type 2, run by Dasman Diabetes Institute at 1 site in Kuwait.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Kuwait. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Stuart R Gray (01413302569, stuart.gray@glasgow.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Grip strength (time frame: Change from baseline to one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Sep 2023.